Estrogen receptor binding (18F-FES PET) and glycolytic activity (18F-FDG PET) predict progression-free survival on endocrine therapy in patients with ER+ breast cancer

Brenda F. Kurland, Lanell M. Peterson, Jean H. Lee, Erin K. Schubert, Erin R. Currin, Jeanne M. Link, Kenneth A. Krohn, David A. Mankoff, Hannah M. Linden

Research output: Contribution to journalArticlepeer-review

54 Scopus citations

Fingerprint

Dive into the research topics of 'Estrogen receptor binding (<sup>18</sup>F-FES PET) and glycolytic activity (<sup>18</sup>F-FDG PET) predict progression-free survival on endocrine therapy in patients with ER<sup>+</sup> breast cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences